Roche amps up its bispecific attack on Eylea with more PhIII data — but just how threatening is it?
Roche has another stack of data to back up its longer-acting challenger to Eylea — although it’s still far from certain just how much they can …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
